June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Ocular surface mast cells exacerbate trigeminal ganglion inflammation and hyperalgesia
Author Affiliations & Notes
  • WonKyung Cho
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Yilin Guan
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Immunology, Harvard Medical School, Boston, Massachusetts, United States
  • Aastha Singh
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Sharad Mittal
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Sunil Chauhan
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   WonKyung Cho None; Yilin Guan None; Aastha Singh None; Sharad Mittal None; Sunil Chauhan None
  • Footnotes
    Support  NEI R01EY029727
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 966. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      WonKyung Cho, Yilin Guan, Aastha Singh, Sharad Mittal, Sunil Chauhan; Ocular surface mast cells exacerbate trigeminal ganglion inflammation and hyperalgesia. Invest. Ophthalmol. Vis. Sci. 2023;64(8):966.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We have shown that mast cells are key immune cells in initiating and promoting ocular surface inflammation. Here we investigated the role of mast cells in neuroinflammation and pain sensitization during ocular inflammation.

Methods : Corneal injury was induced by mechanical removal of the epithelium and anterior stroma in C57BL/6 mice. To visualize mast cells and damaged nerves, corneas were harvested 6h post-injury and stained with β-tubulin III (corneal nerves), and avidin (mast cells) for immunofluorescence analysis. TGs were harvested post-injury and lysates or single-cell suspensions were prepared to measure levels of mast cell-specific tryptase and frequencies of CD45+ inflammatory cells via ELISA and FACS, respectively. To assess direct interaction between mast cells and corneal nerves, primary TGs were co-cultured with mast cells ± mast cell inhibitor cromolyn (100 μM) for 24h. β-tubulin III-stained TGs were assessed under fluorescent microscope and neurite length was quantified using ImageJ. TGs harvested from co-cultures were assessed for the expression of nerve activation marker Substance P (SubP). To assess the in vivo effect of mast cell activation, injured corneas were treated with 2% cromolyn and TG inflammation and hyperalgesia were measured.

Results : Immunofluorescence micrographs showed that ocular surface mast cells juxtapose damaged corneal nerves. Corneal injury resulted in significant upregulation of tryptase levels (p=0.003) and frequencies of CD45+ cells (p=0.01) in the TG, compared to naive controls. In vitro assay demonstrated a 50% decrease in neurite length of TGs co-cultured with mast cells compared to TGs cultured alone (p<0.0001), which was suppressed when treated with cromolyn (p<0.0001). Co-culturing of TGs with mast cells resulted in a 4-fold upregulation in SubP (p<0.0001), compared to TGs cultured alone or co-cultures treated with cromolyn. Moreover, pharmacological inhibition of ocular surface mast cell activation reduced infiltration of mast cells to damaged corneal nerves and resulted in a significant decline in tryptase levels (p<0.01) and CD45+ infiltration in the TG (p=0.03), compared to PBS control. Cromolyn treatment prevented injury-induced hyperalgesia, as shown by decreased eye wipes (p=0.005).

Conclusions : Ocular surface mast cells interact with corneal nerves to augment nerve damage and inflammation in the trigeminal ganglion to induce hyperalgesia.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×